Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
Kawahira M, Kanmura S, Mizuno K, Machida K, Ohtsuka T, Sato M, Enokida H, Yamashita M, Kanekura T, Arima S, Nakamura N, Sugiura T, Yoshimoto K, Kobayashi H, Ishitsuka K, Suzuki S, Ueno S, Ido A.
Kawahira M, et al. Among authors: yamashita m.
PLoS One. 2022 Apr 28;17(4):e0267572. doi: 10.1371/journal.pone.0267572. eCollection 2022.
PLoS One. 2022.
PMID: 35482642
Free PMC article.